Novo Nordisk GLP-1 pill launch impresses but price erosion keeps Citi on the sidelines

Citi raised Novo Nordisk's target price to DKK290 after first-quarter results beat consensus, but kept a neutral rating due to concerns about portfolio price erosion and intensifying obesity-market competition. The bank made modest EPS upgrades of 2-3% for FY2027-FY2031, driven mainly by stronger Wegovy pill assumptions, while leaving 2026 EPS unchanged after cutting sales by 4% and operating income by 7% in constant currency.

Analysis

The key message is not the modest EPS upgrade; it’s that the market is starting to price a widening gap between headline obesity demand and the economics of capturing it. If Novo’s pill drives broader access but also forces lower net realized pricing, the company can still grow units while destroying the scarcity premium that has protected margins. That is a classic late-cycle launch dynamic: volume beats can coexist with multiple compression if payers, employers, and channel partners gain enough leverage.

The bigger second-order effect is competitive. A more scalable oral option expands the addressable market, but it also lowers the barrier for every credible obesity entrant because the buyer pool shifts from specialty adherence to primary-care convenience and payer contracting. Over 12-36 months, that tends to favor manufacturers with the best manufacturing resilience, distribution breadth, and rebate discipline — not necessarily the best trial data. In other words, the winner may be the company that can defend access without conceding too much price, while smaller or later entrants face a harsher reimbursement war.

The market appears focused on the upside to the pill launch and underweighting the possibility that the pill accelerates the normalization of obesity treatment pricing sooner than expected. If that happens, earnings revisions for outer years can remain positive while the equity rerates lower because the market pays for durable margin power, not just sales growth. The first catalyst to watch is not just prescriptions, but the trajectory of net pricing and payer coverage over the next 2-3 quarters; if either weakens, the current neutral stance likely proves too optimistic.

Key Decisions for Investors

• Hold off on adding to NVO until post-launch reimbursement data is visible over the next 1-2 quarters; near-term upside from the pill may be offset by faster-than-expected net price erosion.
• For event-driven exposure, consider a defined-risk long NVO call spread 6-12 months out rather than outright shares: you participate in launch-driven upside while capping downside if margins compress.
• Pair trade: long diversified payers or pharmacy benefit intermediaries versus short NVO over 3-6 months if coverage expansion drives heavier rebate pressure; this expresses the thesis that buyers gain leverage first.
• If already long NVO, tighten risk around the next quarterly update and target partial profit-taking on any rally driven by launch enthusiasm alone; the stock may trade on unit momentum before the market reprices margin quality.